title: A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.
authors.affiliation: Mayo Clinic, Scottsdale, Arizona, USA.
authors.forename: Allison
authors.initials: A
authors.lastname: Rosenthal
authors.affiliation: Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
authors.affiliation: Ohio State, James Cancer Center, Columbus, Ohio, USA.
authors.forename: Craig
authors.initials: C
authors.lastname: Hofmeister
authors.affiliation: Dana Farber Cancer Institute, Boston, Massachusetts, USA.
authors.forename: Jacob
authors.initials: J
authors.lastname: Laubach
authors.affiliation: University of Washington, St Louis, Missouri, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Vij
authors.affiliation: Mayo Clinic, Scottsdale, Arizona, USA.
authors.forename: Amylou
authors.initials: A
authors.lastname: Dueck
authors.affiliation: Mayo Clinic, Scottsdale, Arizona, USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Gano
authors.affiliation: Mayo Clinic, Scottsdale, Arizona, USA. stewart.keith@mayo.edu.
authors.forename: A Keith
authors.initials: AK
authors.lastname: Stewart
mesh_terms: D000368:Aged; D064127:Aurora Kinases / Q000037:antagonists & inhibitors; D001381:Azepines / Q000008:administration & dosage* / Q000009:adverse effects; D000069286:Bortezomib / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D001381:Azepines; C550258:MLN 8237; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000069286:Bortezomib; D064127:Aurora Kinases
keywords: alisertib; aurora kinase; bortezomib; multiple myeloma; relapse